Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Management View CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems and the early ...

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...

Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by the successful ...

Known for its leadership in animal, microbial and plant genomics, GIFS offers PacBio’s HiFi sequencing technology through its Omics and Precision Analytics Laboratory, OPAL, platform.

Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...

Known for its leadership in animal, microbial and plant genomics, GIFS offers PacBio’s HiFi sequencing technology through its Omics and Precision Analytics Laboratory (OPAL) platform.

His role at PacBio will focus on accelerating the adoption of the company's sequencing platforms and enhancing global customer support. PacBio's President and CEO, Christian Henry, expressed ...

Known for its leadership in animal, microbial and plant genomics, GIFS offers PacBio’s HiFi sequencing technology through its Omics and Precision Analytics Laboratory (OPAL) platform. This provides ...

In his new role, Mr. Ruggiero will oversee PacBio’s global sales and service operations, focusing on accelerating the adoption of the company’s sequencing platforms and enhancing customer ...